Observation of rovibrational transitions of HCl, (HCl)2, and H2O-HCl in liquid helium nanodroplets.

We report the infrared spectra of HCl, (HCl)2, and H2O-HCl in liquid helium nanodroplets in the frequency region between 2680 and 2915 cm(-1). For the HCl monomer a line width of 1.0 cm(-1) (H35Cl) corresponding to a lifetime of 5.3 ps was observed. The line broadening indicates fast rotational relaxation similar to that previously observed for HF. For (HCl)2 the free HCl as well as the bound HCl stretching band has been observed. The nu2+ bands of (HCl)2 could be rotationally resolved, and rotational constants were deduced from the spectra. We observed both the allowed and the symmetry forbidden transition. However, the forbidden "broken symmetry" tunneling transition of the mixed dimer shows an intensity that is considerably enhanced compared to the gas phase. Upon the basis of the present measurements we were able to calculate the tunneling splitting in the excited state. The tunneling splitting is found to be reduced by 28% compared to the gas phase. Transitions from the ground state to the Ka=1 level of the free HCl stretch (nu1) are recorded and show considerable line broadening with a line width of 2 cm(-1). The excited state Ka=1 has an additional rotational energy of about 10 cm(-1), thereby allowing fast rotational relaxation by coupling to helium excitations. In addition we observed the HCl stretch of the HCl-H2O dimer, which exhibits an unusually large width (1.7 cm(-1) for H35Cl)) and large red shift (8.5 cm(-1)), compared to the gas-phase values. The large-amplitude motion originating from the libration mode of the HCl-H2O complex is supposed to act as a fast relaxation manifold.

Etoposide in combination with cyclophosphamide and total body irradiation or busulfan as conditioning for marrow transplantation in adults and children.

PURPOSE: In an attempt to intensify conditioning therapy for bone marrow transplantation of hematologic malignancies, a retrospective three center evaluation of escalating doses of etoposide added to cyclophosphamide and either total body irradiation or busulfan was undertaken. METHODS AND MATERIALS: Seventy-six patients who received etoposide (25-65 mg/kg) added to cyclophosphamide (60-120 mg/kg) and either total body irradiation (12.0-13.2 Gy) or busulfan (12-16 mg/kg) were evaluable for toxicity. Fifty-one of the evaluable patients received allogeneic transplants, while twenty-six received autologous transplants. A comparative analysis of toxicities according to conditioning regimen, donor source and etoposide dose was made. RESULTS: Similar toxicities were observed among the treatment groups with the exception of more frequent skin (p = 0.003) and life threatening hepatic toxicities (p = 0.01) in the busulfan treated patients. Life threatening or fatal toxicities were not influenced by donor source, either when analyzed by treatment group or etoposide dose. Etoposide at a dose of 60-65 mg/kg in combination with TBI and cyclophosphamide was associated with a significantly increased incidence of life threatening or fatal toxicities compared with a combination using a dose of 25-50 mg/kg (15 of 24 vs. 5 of 20; p = 0.013). The maximally tolerated dose of etoposide in combination with busulfan and cyclophosphamide cannot be definitively established in this analysis in part due to the heterogeneity of the patient population and treatment schemes. CONCLUSION: Although toxicities with bone marrow transplant preparative regimens containing etoposide in combination with cyclophosphamide and total body irradiation or busulfan were frequently severe, treatment related mortality risk was believed to be acceptably low.

Relationships between oral mucositis and treatment variables in bone marrow transplant patients.

The pattern of oral mucositis and related treatment variables was studied in 20 bone marrow transplant patients. Patients received either total body irradiation (TBI) or busulfan in combination with cyclophosphamide and etoposide as pretransplant conditioning. Daily oral assessment scores were analyzed. Mucosal changes began approximately 2 days before transplant and peaked approximately 8 days after transplant. There was a trend for patients receiving TBI to have slightly higher oral scores during the first week posttransplant than patients receiving busulfan. The TBI patients averaged almost twice the number of days of continuous intravenous morphine infusion for oral pain and 6 additional days of total parenteral nutrition when compared with patients receiving busulfan. Subjects who died during aplasia manifested mucositis that gradually worsened and did not return to baseline. Differences in oral status based on type of transplant, either autologous or allogeneic, were not shown in this study.